Bath, UK, 19th June, 2014. Atlas Genetics Ltd (“Atlas” or the “Company”), the diagnostic company developing ultra-rapid point-of-care (POC) tests for a range of infectious diseases, has won the “Best for Innovation” award in the BVCA Management Team Awards 2014 for the South West region.
The prize was given out by the British Private Equity and Venture Capital Association (BVCA), the industry body and public policy advocate for the private equity and venture capital industry in the UK. The BVCA Management Team Awards are an annual celebration of the best and brightest UK businesses which are supported by private equity and venture capital. The “Best for Innovation” award aims to recognise the achievements of the management teams of eligible companies in driving innovation.
Atlas Genetics has developed the io system, a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs). The io system will make it possible, for the first time, to carry out a broad range of infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories. This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of STIs, where a significant proportion of patients fail to return for test results or follow-on treatment.
John Clarkson, CEO of Atlas, said: “I’m delighted that the work of Atlas Genetics has been recognised through this prestigious award. We are at the forefront of clinical science in the development of fast and accurate tests for infectious diseases. The ability for clinicians and GPs to diagnose and treat in the same session is important for the prevention of onward transmission of infection. The underlying technology is based on long term collaborative research with the University of Bath, and this award is testament to the strength of that collaboration and the scale of innovation that it has fostered.”